Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

ClinicalTrials.gov ID: NCT01345669

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01345669. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomised, double-blind phase III trial will be performed in patients with head and neck squamous cell carcinoma (HNSCC). The objectives of the trial are to compare the efficacy and safety of afatinib (BIBW 2992) with placebo as adjuvant therapy to patients who have received definitive chemo-radiotherapy.

Study identification

NCT ID
NCT01345669
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
617 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 17, 2011 (Actual)
Primary completion
Sep 12, 2016 (Actual)
Completion
Sep 12, 2016 (Actual)
Last update posted
Dec 7, 2017

2011 – 2016

United States locations

U.S. sites
15
U.S. states
13
U.S. cities
15
Facility City State ZIP Site status
1200.131.00171 Boehringer Ingelheim Investigational Site Little Rock Arkansas — —
1200.131.00181 Boehringer Ingelheim Investigational Site Orange California — —
1200.131.00177 Boehringer Ingelheim Investigational Site Aurora Colorado — —
1200.131.00185 Boehringer Ingelheim Investigational Site New Haven Connecticut — —
1200.131.00173 Boehringer Ingelheim Investigational Site Baltimore Maryland — —
1200.131.00176 Boehringer Ingelheim Investigational Site Boston Massachusetts — —
1200.131.00182 Boehringer Ingelheim Investigational Site Omaha Nebraska — —
1200.131.00175 Boehringer Ingelheim Investigational Site Lebanon New Hampshire — —
1200.131.00179 Boehringer Ingelheim Investigational Site Stony Brook New York — —
1200.131.00188 Boehringer Ingelheim Investigational Site The Bronx New York — —
1200.131.10200 Boehringer Ingelheim Investigational Site Winston-Salem North Carolina — —
1200.131.00172 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania — —
1200.131.00184 Boehringer Ingelheim Investigational Site San Antonio Texas — —
1200.131.00198 Boehringer Ingelheim Investigational Site Spokane Valley Washington — —
1200.131.00183 Boehringer Ingelheim Investigational Site Wenatchee Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 147 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01345669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 7, 2017 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.